In downstream processing of biopharmaceutical products, protein aggregation presents one of the main risks in terms of ...
RBC Capital analyst Kenneth Lee maintained a Buy rating on Rithm Capital (RITM – Research Report) yesterday and set a price target of $13.00.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback